| Literature DB >> 1487411 |
E H Kraut1, J Bendetti, S P Balcerzak, J H Doroshow.
Abstract
Thirty-seven patients with advanced soft tissue sarcoma were treated with merbarone utilizing a daily intravenous schedule for five days. Only one partial response was observed in the thirty-three evaluable patients. The major toxicities were renal, with elevation of creatinine and/or proteinuria, and gastrointestinal, with mild to moderate nausea and vomiting. Merbarone in this dose and schedule has minimal activity in soft tissue sarcoma.Entities:
Mesh：
Substances：
Year: 1992 PMID： 1487411 DOI： 10.1007/bf00944194
Source DB: PubMed Journal: Invest New Drugs ISSN： 0167-6997 Impact factor: 3.850